In a nutshell This study examined the safety and effectiveness of stem cell transplantation (SCT) in elderly patients with multiple myeloma (MM) aged 65 or older compared to younger patients. The authors concluded that SCT was equally as safe and effective for patients in both age groups. Some background Multiple myeloma is a complex type of...
Read MoreMultiple Myeloma Posts on Medivizor
Carfilzomib, thalidomide and dexamethasone in the treatment of multiple myeloma
In a nutshell This study looked at the safety and effectiveness of carfilzomib (Kyprolis), thalidomide (Thalomid) and dexamethasone (Decadron) in the treatment of patients with multiple myeloma. Researchers concluded that this treatment plan is safe and effective in these patients. Some background Multiple myeloma is a cancer of the bone marrow. It is...
Read MoreT-cell therapy for relapsed/refractory multiple myeloma
In a nutshell This study aimed to investigate the safety of a T-cell therapy, bb2121, for patients with relapsed or unresponsive multiple myeloma. This study concluded that bb2121 shows antitumor activity in these patients. Some background Early studies indicate that bb2121 has potential to treat relapsed or unresponsive...
Read MoreEvaluating ixazomib maintenance therapy for patients with multiple myeloma
In a nutshell This study evaluated the safety and effectiveness of ixazomib (Ninlaro) maintenance therapy in patients with multiple myeloma (MM). This study concluded that ixazomib is a safe and effective maintenance therapy for these patients. Some background Multiple myeloma is a type of cancer of the bone marrow that can lead to abnormal...
Read MoreNanodrugs
Nanodrugs have been around for some time. In fact, over 250 drugs using nanotechnology that have been approved by the FDA and are in clinical use. The name nanodrug or nanopharmaceuticals refers to the size of the particle that is created to house the medication. A nano is very tiny: nanoparticles are between 1 and 100 nanometers in at least one of its...
Read MoreSearching for patients with recurrent multiple myeloma to test daratumumab
In a nutshell This phase 2 trial is evaluating how well daratumumab (Darzalex) works in treating patients with multiple myeloma (MM) that has come back after a stem cell transplant (SCT). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This trial is recruiting in Houston,...
Read MoreEvaluating busulfan plus melphalan conditioning for patients with multiple myeloma before stem cell transplantation
In a nutshell This study evaluated the safety and effectiveness of busulfan (Myleran) plus melphalan (Alkeran) compared to melphalan alone for patients with multiple myeloma (MM) before autologous stem cell transplantation (ASCT). This study concluded that the combination treatment was more effective for these patients. Some background...
Read MoreEvaluating isatuximab plus pomalidomide and dexamethasone for non-responsive multiple myeloma
In a nutshell This study evaluated isatuximab, pomalidomide (Imnovid) and dexamethasone (Decadron) for recurrent or non-responsive multiple myeloma (MM). This study concluded that this treatment combination was safe and effective for these patients. Some background There are several treatment options for patients with MM. Most initial...
Read MoreDoes genetics impact how long patients respond to treatment for recurrent multiple myeloma?
In a nutshell This study evaluated whether certain genetic markers affect how long patients respond to treatment for recurrent multiple myeloma (MM). This study found that patients without these genetic markers had better outcomes compared to patients who did have them. Some background Multiple myeloma is a type of cancer of the bone marrow that can...
Read MoreExpert recommendations for the treatment of patients with multiple myeloma.
In a nutshell This article provided recommendations for the treatment of patients with multiple myeloma (MM). Some background Multiple myeloma is a type of cancer of the bone marrow that can lead to abnormal immune cells. High-dose chemotherapy followed by a stem cell transplant (SCT) remains a key part of treatment for patients with MM. There are two...
Read MoreEvaluating outcomes after salvage stem cell transplantation for patients with recurrent multiple myeloma
In a nutshell This study evaluated the outcomes of patients with recurrent multiple myeloma (MM) after a stem cell transplant (SCT). This study concluded that these patients had a lower quality of life up to 2 years after treatment. Some background Multiple myeloma is a type of cancer of the bone marrow that can lead to abnormal immune cells. For...
Read MoreSearching for patients to try a new treatment for multiple myeloma.
In a nutshell This study will investigate the effects of a new treatment, GSK2857916, in patients with multiple myeloma (MM). Overall response will be the main outcome measured. The details There are many treatment options for MM. However, some patients do not respond to treatments or relapse. New therapies are being developed for these patients....
Read More
